Иванощук Д. Е., Шахтшнейдер Е. В. СОВРЕМЕННЫЙ ВЗГЛЯД НА ВОПРОСЫ АТЕРОСКЛЕРОЗА ОБЗОР МАТЕРИАЛОВ 84-ГО КОНГРЕССА ЕВРОПЕЙСКОГО ОБЩЕСТВА АТЕРОСКЛЕРОЗА. Атеросклероз. 2016;12(3):78-84.
1. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. doi: 10.1093/eurheartj/ehw106
2. Nordestgaard BG, Langsted A, Mora S et al. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory European Federation of Clinical Chemistry and Laboratory Medicine. Joint Publication: Eur Heart J. 2016 Apr 26. pii: ehw152. [Epub ahead of print] and Clin Chem. 2016 May 27. pii: clinchem.2016.258897. [Epub ahead of print]
3. http://www.eas2016.kenes.com/Documents/ Opening%20Cermony%20Highlights.pdf
4. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35:2146-57.
5. Wang Y, McNutt MC, Banfi S et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl AcadSci USA 2015;112:11630-5.
6. Musunuru K, Pirruccello JP, Do R et al. Exome Sequencing, ANGPTL3Mutations, and Familial Combined Hypolipidemia. N Engl J Med 2010;363:2220-7.
7. Pisciotta L, Favari E, Magnolo L et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. CircCardiovasc Genet 2012;5:42-50.
8. Gusarova V, Alexa CA, Wang Y et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res 2015;56:1308-17.
9. Gaudet D, Gipe DA, Khoury É et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: a single arm, open-label, proof of concept study.84nd EAS Congress, Innsbruck, Austria, May 29 - June 1, 2016.P. 247.
10. Gaudet D, Saheb S, Bruckert E et al. A pilot study of MBX 8025 in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). 84nd EAS Congress, Innsbruck, Austria, May 29 - June 1, 2016. P. 244.
11. Raal FJ, Honarpour N, Blom DJ et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. lipid-lowering therapy. Circulation 2011;124:2202-7.
12. Raal FJ, Pilcher GJ, Panz VR et al. Reductionin mortality in subjects with homozygous familialhypercholesterolemia associated with advances.
13. World Health Organization. Obesity and overweight (2015). Available at http://www.who.int/ mediacentre/factsheets/fs311/en/
14. Fischer J, Lefèvre C, Morava E et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Gen 2007; 39:28-30.
15. Bartlet A, Heeren J. Adipose tissue browning and metabolic health. J Nat Rev Endocrinol 2014;10:24- 36.
16. Chu AY, Workalemahu T, Paynter NP et al. Novel locus including FGF21 is associated with dietary macronutrient intake. Hum Mol Genet 2013;22:1895- 902.
17. Talukdar S, Owen BM, Song P et al. FGF21 regulates sweet and alcohol preference. Cell Metab 2016;23:344-9.
18. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med 2013;369:1336-43.
19. Wen CP, Wu X. Stressing harms of physical inactivity to promote exercise. Lancet 2012;380:192-3.
20. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. doi: 10.1093/eurheartj/ehw106
21. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
22. Gieger C, Geistlinger L, Altmaier E et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008;4: e1000282.
23. Altmaier E, Menni C, Heier M et al. The pharmacogenetic footprint of ACE inhibition: A population-based metabolomics study. PLoS One 2016;11: e0153163.
24. Shin SY, Fauman EB, Petersen AK et al. An atlas of genetic influences on human blood metabolites. Nat Genet 2014;46:543-50.
25. Finan B, Yang B, Ottaway N et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015;21:27- 36.
26. UPDATED: Ionis shares plunge as safety crisis deepens, GSK abandons PhIII. https://www. fiercebiotech.com/ionis-reveals-safety-issues-two-phiii-studies-after-gsk-delays-a-trial
